Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary


yttrium Y 90-DOTA-girentuximab 
A radioimmunoconjugate comprised of girentuximab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90-DOTA-girentuximab binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:yttrium Y 90 DOTA chimeric monoclonal antibody cG250